News Center
With the tenet of "Healthy China, Dedicated commitment", Linuo Pharmaceuticals increases cooperation and association with external scientific research institutes while innovating and developing independently.
27
2026
-
02
[Building a Learning-Oriented Team—Lesson 19] Learn the New Regulations, Uphold Compliance! Linuo Pharmaceutical Conducts Special Training on the Implementation Regulations of the Drug Administration Law!
Classification：
Corporate News
Drug safety is closely linked to people’s health, and the rule of law provides a solid framework to support the development of the pharmaceutical industry. On January 27, the newly revised “Implementation Regulations of the People’s Republic of China Drug Administration Law” (hereinafter referred to as the “Regulations”) were officially promulgated. These Regulations weave a robust legal network for drug safety, refine regulatory requirements, and establish clear guidelines for the full lifecycle management of drugs—from research and development through production, distribution, and use—directly impacting enterprises’ compliance operations and high-quality development.
To thoroughly grasp the core principles of the Regulations at the earliest opportunity, accurately understand the policy direction, and effectively enhance compliance awareness and professional competence across the board, Linuo Pharmaceutical swiftly took action by urgently organizing a special internal training session. With a spirit of rapid response and proactive learning, the company is committed to ensuring that the spirit of the Regulations takes root and is put into practice. All employees from the company’s production, quality, and other key functional departments attended the training, making every effort to ensure comprehensive and thorough coverage of the Regulations without any blind spots.
The training content focuses on the core provisions of the Regulation, with a particular emphasis on areas closely related to regulatory requirements for the pharmaceutical industry and enterprises’ compliant operations. The training provides an in-depth analysis of key policy changes, helping participating employees accurately grasp the Regulation’s essence, effectively mitigate compliance risks, and align their job responsibilities with the new regulatory requirements. To assess learning outcomes and solidify acquired knowledge, the company organized a company-wide exam after the training, ensuring that all participants truly understand the key points of the new regulations and can apply their learning in practice.
This training session is not only a concrete manifestation of Linuo Pharmaceutical’s commitment to the philosophy of “building a learning-oriented team,” but also a clear demonstration of the company’s dedication to upholding the bottom line of drug safety and practicing compliant business operations. In response to the implementation of the new regulations, the company has adopted an attitude of “acting promptly upon receiving directives and integrating learning with practical application,” swiftly organizing specialized study sessions to help all employees thoroughly understand the new regulations and perform their duties in compliance. This ensures that the knowledge gained from the Regulations is effectively translated into concrete actions aimed at safeguarding drug safety and driving the company’s high-quality development—using professional expertise to firmly establish a robust defense for public medication safety.
Related news
2026-05-18
On May 16–17, Wu Xiaobo, known as “China’s foremost financial writer” and a renowned entrepreneur, led a delegation to visit and inspect Keyuan Pharmaceutical (stock code: 301281.SZ). The group focused on the company’s achievements in integrating smart manufacturing with digital AI technologies in the pharmaceutical sector, engaged in in-depth discussions with its core management team, and expressed high praise for the company’s practical approach to driving industrial upgrading through digital and intelligent transformation. Gao Yuankun, Chairman and President of Linuo Group, along with Li Hongfu, Chairman of Keyuan Pharmaceutical, and Wei Zhiguo, President of the company, accompanied the delegation during the visit.
ADD：#30766 Jingshidong Road, Linuo High-tech Park, Jinan, Shandong Province, P. R. China